Response to: Letter to the Editor Regarding “Comparative Effectiveness of FF/1 UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy”
Year: 2026
Type: letter
Abstract: Budesonide/glycopyrrolate/ formoterol fumarate; Chronic obstructive pulmonary disease; Exacerbations; Fluticasone furoate/umeclidinium/vilanterol; Real-world comparative effectiveness study We thank Quint et al. [1] for their interest in our recent article describing comparative real-world effectiveness of single-inhaler triple therapies (SITTs) in patients with COPD stepping up from dual therapy [2], and welcome the opportunity to respond to the points raised in their letter on the limitations and technical complexities of our analyses.The letter highlights two areas to be considered when interpreting our comparative effectiveness results.The first is the inherent limitations associated with use of open claims data.We agree that lack of direct verification of insurance eligibility, inclusion of overlapping records, inconsistent capture of encounters, and incomplete longitudinal follow-up are limitations of open claims data, and have highlighted these in the Methods and Discussion sections of our paper.However, it is worth
Source: Advances in Therapy
Institutions: Imperial College London, GlaxoSmithKline (Canada), McMaster University, GlaxoSmithKline (United Kingdom), Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Center for Infection and Immunity of Lille, GlaxoSmithKline (United States), University of Kentucky, COPD Foundation
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W7125398422